Navigation Links
Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis
Date:5/18/2009

th in Orlando, Florida.

About PX-866

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Aberrant activation and regulation of PI-3 kinase is implicated in a large proportion of human cancers including breast, glioma, colon, ovarian, prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous administration. The compound has been shown to have anti-tumor activity both as a single agent and in combination with other agents in a number of human tumor models. Oncothyreon initiated a Phase 1 trial of PX-866 in patients with advanced metastatic cancer in June 2008.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward-looking, including statements related to future preclinical and clinical development plans for PX PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
4. Phase III Trial Finds Pharmaxis Bronchitol Effective
5. New nanoparticle vaccine is more effective but less expensive
6. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
11. DNA sensors found to be an effective artificial nose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Replikins Ltd. today released ... the Ebola virus. Before the current outbreaks, the mean ... 100 amino acids) between 1995 and 2002 was 1.1; ... in 2012, and sixteen-fold in 2013, thus predicting the ... this technology has been shown to be able to ...
(Date:7/30/2014)... Selexis SA , a serial innovation ... mammalian cell line development, announced today new data from ... presented at the 10th Annual Cell Line Development ... 10, 2014 at the Double Tree by Hilton Berkeley ... will be presented during an oral presentation: , Title: ...
(Date:7/30/2014)... Calif. , July 30, 2014   ... on the Fully Integrated Lifecycle Mission Support Services ... Space Administration (NASA). Under the terms of the ... Research Center at Moffett Field, Calif. In particular, ... for bioscience flight development projects on the International ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 July 30, ... @APDN), a biotechnology firm that provides DNA-based authentication and ... Hogan, Ph.D. Vice President of Life Sciences, a newly ... , Dr. Hogan will lead APDN’s drive to ... relationships with biotech and healthcare customers, provide guidance to ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... American Stock Exchange(R),(Amex(R)) today listed the common ... symbol RNN., Rexahn Pharmaceuticals is a ... discover, develop and commercialize,innovative treatments for cancer, ... unmet medical needs. Rexahn,s compounds are designed,to ...
... Judges for Nikon Small World, MELVILLE, N.Y., ... received a record number of entries for the ... by over 300,images. The oldest and most respected ... world,s best photomicrographers who create beautiful,imagery while showing ...
... Informed Medical Communications,(IMC), a leading provider of peer-to-peer ... appointment of Bert,Marchio to the position of Executive ... ), Marchio brings to IMC over 20 ... both the public and private sectors, with the ...
Cached Biology Technology:American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc. 2Nikon Instruments Receives Record Number of Entries for Nikon Small World 2Informed Medical Communications Appoints New Chief Financial Officer 2
(Date:7/30/2014)... that David L. Kaplan, Ph.D., will head the brand-new, ... as editor-in-chief. With the first issue slated for publication ... research in the rapidly burgeoning field of biomaterials, the ... with living or biological systems. , "This new journal ... the field of biomaterials over the past decade and ...
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... could be as simple as inserting a medicated, disappearing ... Washington bioengineers have discovered a potentially faster way to ... HIV. Their method spins the drug into silk-like fibers ... higher doses of the drug than possible with other ... could offer women a potentially more effective, discreet way ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... of human growth hormone (GH) by healthy elderly people found ... body composition but not in body weight or other clinically ... increased rates of unhealthy side effects such as soft tissue ... breast development. They were also somewhat more likely to ...
... to produce useful proteins could be an inexpensive ... the Flanders Interuniversity Institute for Biotechnology (VIB) at ... seeds proteins that have a very strong resemblance ... antibody variants are just as active as the ...
... of Warwick reveals that a Nobel Prize brings more than ... two years to your life. , The research by Professor ... Matthew Rablen, (a former Warwick postgraduate researcher now a government ... and Immortality". , The researchers carried out their study ...
Cached Biology News:Growth hormone is not the anti-aging bullet for healthy adults 2Growth hormone is not the anti-aging bullet for healthy adults 3Producing medicines in plant seeds 2Producing medicines in plant seeds 3New research says winning a Nobel Prize adds nearly 2 years to your lifespan 2
... or Isolated Sequence) siRNA Test System is ... evaluation of a potential of any DNA ... for RNA interference (RNAi). Current computer-based RNAi ... the probability of selected sequence to be ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
... formulated for covering tissue sections and cell preparations immunohistochemically stained ... , ... Application: Vision Mount ... that require an aqueous mounting medium, or those that do ...
Biology Products: